Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Clinical trial NCT02648477 · COMPLETED

Trial details

NCT number: NCT02648477
Sponsor: City of Hope Medical Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Estrogen Receptor Negative Estrogen Receptor Positive HER2/Neu Negative Progesterone Receptor Negative Progesterone Receptor Positive Stage IV Breast Cancer Triple-Negative Breast Carcinoma

Start date: 2016-03-28
Primary completion: 2022-04-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.